跳转至内容
Merck
所有图片(1)

文件

SML3156

Sigma-Aldrich

ALW-II-41-27

≥98% (HPLC)

别名:

ALW-II-247, N-(5-(4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenylcarbamoyl)-2-methylphenyl)-5-(thiophen-2-yl)nicotinamide, N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]benzamide

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C32H32F3N5O2S
CAS号:
1186206-79-0
分子量:
607.69
MDL號碼:
MFCD25372028
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

O=C(NC1=CC=C(CN2CCN(CC)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(NC(C4=CC(C5=CC=CS5)=CN=C4)=O)=C3

InChI

1S/C32H32F3N5O2S/c1-3-39-10-12-40(13-11-39)20-23-8-9-26(17-27(23)32(33,34)35)37-30(41)22-7-6-21(2)28(16-22)38-31(42)25-15-24(18-36-19-25)29-5-4-14-43-29/h4-9,14-19H,3,10-13,20H2,1-2H3,(H,37,41)(H,38,42)

InChI 密鑰

HYWXBDQAYLPMIX-UHFFFAOYSA-N

生化／生理作用

ALW-II-41-27 is an RG-25 (RG25) structural analog that exhibits enhanced type II kinase inhibitor activity against ephrin type-A receptor 2/EphA2/ECK (IC50 = 11 nM vs 770 nM with NG25) by targeting the ATP-binding pocket and an allosteric site next to the “DFG” motif. ALW-II-41-27 inhibits constitutive and ephrin A1-induced EphA2 tyrosine phosphorylation (0.1-1 μM; H358), effectively suppressing EphA2-dependent cancer survival in vitro (0.1-1 μM for 72 hrs; NSCLC) and xenograft tumor growth in mice in vivo (15-30 mg/kg b.i.d. i.p.; H358 NSCLC & A375 melanoma). Note: ALW-II-41-27 and RG-25 (RG25) display very similar kinase-targeting profiles with EphA2 being a notable exception, RG25 can therefore serve as a control for ALW-II-41-27 when probing EphA2-mediated cellular functions.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
Terai, et al.
ACS chemical biology, 10, 2687-2696 (2018)
Katherine R Amato et al.
The Journal of clinical investigation, 124(5), 2037-2049 (2014-04-10)
Genome-wide analyses determined previously that the receptor tyrosine kinase (RTK) EPHA2 is commonly overexpressed in non-small cell lung cancers (NSCLCs). EPHA2 overexpression is associated with poor clinical outcomes; therefore, EPHA2 may represent a promising therapeutic target for patients with NSCLC.
Katherine R Amato et al.
Cancer research, 76(2), 305-318 (2016-01-09)
Despite the success of treating EGFR-mutant lung cancer patients with EGFR tyrosine kinase inhibitors (TKI), all patients eventually acquire resistance to these therapies. Although various resistance mechanisms have been described, there are currently no FDA-approved therapies that target alternative mechanisms
Yongmun Choi et al.
Bioorganic & medicinal chemistry letters, 19(15), 4467-4470 (2009-06-26)
The Eph family of receptor tyrosine kinases has drawn growing attention due to their role in regulating diverse biological phenomena. However, pharmacological interrogation of Eph kinase function has been hampered by a lack of potent and selective Eph kinase inhibitors.
W Song et al.
Oncogene, 36(40), 5620-5630 (2017-06-06)
Basal-like/triple-negative breast cancers (TNBCs) are among the most aggressive forms of breast cancer, and disproportionally affects young premenopausal women and women of African descent. Patients with TNBC suffer a poor prognosis due in part to a lack of molecularly targeted
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门